Keyword Search Results for "lipid-modifying"

Blazing, M. A., De Lemos, J. A., Dyke, C. K., Califf, R. M., Bilheimer, D., Braunwald, E. The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy Am Heart J. 2001;142(2):211-7.

Cannon, C. P., McCabe, C. H., Belder, R., Breen, J., Braunwald, E. Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial Am J Cardiol. 2002;89(7):860-1.

Cannon, C. P. The next step in cardiovascular protection Atheroscler Suppl. 2003;4(5):9-Mar. Abstract

Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-504.

Ray, K. K., Cannon, C. P. Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biology Curr Opin Lipidol. 2004;15(6):637-43. Abstract

de Lemos, J. A., Blazing, M. A., Wiviott, S. D., Lewis, E. F., Fox, K. A., White, H. D., Rouleau, J. L., Pedersen, T. R., Gardner, L. H., Mukherjee, R., Ramsey, K. E., Palmisano, J., Bilheimer, D. W., Pfeffer, M. A., Califf, R. M., Braunwald, E. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial JAMA. 2004;292(11):1307-16.

Dupuis, J., Tardif, J. C., Rouleau, J. L., Ricci, J., Arnold, M., Lonn, E., Roux, R., Title, L. M., Amyot, R., Bonafede, N., Woo, A., Cannon, C. P. Intensity of lipid lowering with statins and brachial artery vascular endothelium reactivity after acute coronary syndromes (from the BRAVER trial) Am J Cardiol. 2005;96(9):1207-13. Abstract

Ray, K. K., Cannon, C. P. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes J Am Coll Cardiol. 2005;46(8):1425-33. Abstract

Ray, K. K., Cannon, C. P. Early time to benefit with intensive statin treatment: could it be the pleiotropic effects? Am J Cardiol. 2005;96(5A):54F-60F. Abstract

Ray, K. K., Cannon, C. P., McCabe, C. H., Cairns, R., Tonkin, A. M., Sacks, F. M., Jackson, G., Braunwald, E. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial J Am Coll Cardiol. 2005;46(8):1405-10.

Reid, I. R., Tonkin, A., Cannon, C. P. Comparison of the effects of pravastatin and atorvastatin on fracture incidence in the PROVE IT-TIMI 22 trial--secondary analysis of a randomized controlled trial Bone. 2005;37(2):190-1.

Ridker, P. M., Cannon, C. P., Morrow, D., Rifai, N., Rose, L. M., McCabe, C. H., Pfeffer, M. A., Braunwald, E. C-reactive protein levels and outcomes after statin therapy N Engl J Med. 2005;352(1):20-8.

Ridker, P. M., Morrow, D. A., Rose, L. M., Rifai, N., Cannon, C. P., Braunwald, E. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial J Am Coll Cardiol. 2005;45(10):1644-8.

Smith, C. S., Cannon, C. P., McCabe, C. H., Murphy, S. A., Bentley, J., Braunwald, E. Early initiation of lipid-lowering therapy for acute coronary syndromes improves compliance with guideline recommendations: observations from the Orbofiban in Patients with Unstable Coronary Syndromes (OPUS-TIMI 16) trial Am Heart J. 2005;149(3):444-50. Abstract

Wiviott, S. D., Cannon, C. P., Morrow, D. A., Ray, K. K., Pfeffer, M. A., Braunwald, E. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy J Am Coll Cardiol. 2005;46(8):1411-6.

Ahmed, S., Cannon, C. P., Murphy, S. A., Braunwald, E. Acute coronary syndromes and diabetes: Is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial Eur Heart J. 2006;27(19):2323-9.

Atar, S., Cannon, C. P., Murphy, S. A., Rosanio, S., Uretsky, B. F., Birnbaum, Y. Statins are associated with lower risk of gastrointestinal bleeding in patients with unstable coronary syndromes: analysis of the Orbofiban in Patients with Unstable coronary Syndromes-Thrombolysis In Myocardial Infarction 16 (OPUS-TIMI 16) trial Am Heart J. 2006;151(5):976 e1-6. Abstract

Cannon, C. P., Steinberg, B. A., Murphy, S. A., Mega, J. L., Braunwald, E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy J Am Coll Cardiol. 2006;48(3):438-45. Abstract

Mega, J. L., Morrow, D. A., Cannon, C. P., Murphy, S., Cairns, R., Ridker, P. M., Braunwald, E. Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy Journal of Thrombosis and Thrombolysis. 2006;22(1):71-76. Abstract

Ray, K. K., Bach, R. G., Cannon, C. P., Cairns, R., Kirtane, A. J., Wiviott, S. D., McCabe, C. H., Braunwald, E., Gibson, C. M. Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS Eur Heart J. 2006;27(19):2310-6.

Ray, K. K., Morrow, D. A., Shui, A., Rifai, N., Cannon, C. P. Relation between soluble intercellular adhesion molecule-1, statin therapy, and long-term risk of clinical cardiovascular events in patients with previous acute coronary syndrome (from PROVE IT-TIMI 22) Am J Cardiol. 2006;98(7):861-5. Abstract

Scirica, B. M., Morrow, D. A., Cannon, C. P., Ray, K. K., Sabatine, M. S., Jarolim, P., Shui, A., McCabe, C. H., Braunwald, E. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study J Am Coll Cardiol. 2006;47(11):2326-31.

Wiviott, S. D., Cannon, C. P. Update on lipid-lowering therapy and LDL-cholesterol targets Nat Clin Pract Cardiovasc Med. 2006;3(8):424-36. Abstract

Wiviott, S. D., Cannon, C. P. The safety and efficacy of achieving very low LDL-cholesterol concentrations with high dose statin therapy Curr Opin Lipidol. 2006;17(6):626-30. Abstract

Wiviott, S. D., de Lemos, J. A., Cannon, C. P., Blazing, M., Murphy, S. A., McCabe, C. H., Califf, R., Braunwald, E. A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22 Circulation. 2006;113(11):1406-14. Abstract

de Lemos, J. A., Wiviott, S. D., Murphy, S. A., Blazing, M. A., Lewis, E. F., Califf, R. M., Pfeffer, M. A., Braunwald, E. Evaluation of the National Cholesterol Education Program Adult Treatment Panel III algorithm for selecting candidates for statin therapy: insights from the A to Z trial Am J Cardiol. 2006;98(6):739-42.

Cannon, C. P., Husted, S., Harrington, R. A., Scirica, B. M., Emanuelsson, H., Peters, G., Storey, R. F. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial J Am Coll Cardiol. 2007;50(19):1844-51. Abstract

Murphy, S. A., Cannon, C. P., Wiviott, S. D., de Lemos, J. A., Blazing, M. A., McCabe, C. H., Califf, R. M., Braunwald, E. Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials) Am J Cardiol. 2007;100(7):1047-51. Abstract

de Lemos, J. A., Morrow, D. A., Blazing, M. A., Jarolim, P., Wiviott, S. D., Sabatine, M. S., Califf, R. M., Braunwald, E. Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial J Am Coll Cardiol. 2007;50(22):2117-24. Abstract

Brilakis, E. S., de Lemos, J. A., Cannon, C. P., Wiviott, S. D., Murphy, S. A., Morrow, D. A., Sabatine, M. S., Banerjee, S., Blazing, M. A., Califf, R. M., Braunwald, E. Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials) Am J Cardiol. 2008;102(5):552-8. Abstract

Cannon CP, Giugliano RP, Blazing MA, Harrington RA, Peterson JL, Sisk CM, Strony J, Musliner TA, McCabe CH, Veltri E, Braunwald E, Califf RM. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J. 2008;156:826-32. Abstract

Cannon, C. P. Combination therapy in the management of mixed dyslipidaemia J Intern Med. 2008;263(4):353-65. Abstract

Giraldez, R. R., Giugliano, R. P., Mohanavelu, S., Murphy, S. A., McCabe, C. H., Cannon, C. P., Braunwald, E. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis J Am Coll Cardiol. 2008;52(11):914-20.

Iakoubova, O. A., Sabatine, M. S., Rowland, C. M., Tong, C. H., Catanese, J. J., Ranade, K., Simonsen, K. L., Kirchgessner, T. G., Cannon, C. P., Devlin, J. J., Braunwald, E. Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study J Am Coll Cardiol. 2008;51(4):449-55.

Lotfi, A., Schweiger, M. J., Giugliano, G. R., Murphy, S. A., Cannon, C. P. High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients--a Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) analysis Am Heart J. 2008;155(5):954-8.

McLean, D. S., Ravid, S., Blazing, M., Gersh, B., Shui, A., Cannon, C. P. Effect of statin dose on incidence of atrial fibrillation: data from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) and Aggrastat to Zocor (A to Z) trials Am Heart J. 2008;155(2):298-302. Abstract

Morrow, D. A., Wang, Y., Croce, K., Sakuma, M., Sabatine, M. S., Gao, H., Pradhan, A. D., Healy, A. M., Buros, J., McCabe, C. H., Libby, P., Cannon, C. P., Braunwald, E., Simon, D. I. Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial Am Heart J. 2008;155(1):49-55.

Sabatine, M. S., Ploughman, L., Simonsen, K. L., Iakoubova, O. A., Kirchgessner, T. G., Ranade, K., Tsuchihashi, Z., Zerba, K. E., Long, D. U., Tong, C. H., Packard, C. J., Pfeffer, M. A., Devlin, J. J., Shepherd, J., Campos, H., Sacks, F. M., Braunwald, E. Association between ADAMTS1 matrix metalloproteinase gene variation, coronary heart disease, and benefit of statin therapy Arterioscler Thromb Vasc Biol. 2008;28(3):562-7. Abstract

Cannon, C. P., Dansky, H. M., Davidson, M., Gotto, A. M., Jr., Brinton, E. A., Gould, A. L., Stepanavage, M., Liu, S. X., Shah, S., Rubino, J., Gibbons, P., Hermanowski-Vosatka, A., Binkowitz, B., Mitchel, Y., Barter, P. Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib Am Heart J. 2009;158(4):513-519 e3. Abstract

Gibson, C. M., Pride, Y. B., Hochberg, C. P., Sloan, S., Sabatine, M. S., Cannon, C. P. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy J Am Coll Cardiol. 2009;54(24):2290-5.

Mega, J. L., Morrow, D. A., Brown, A., Cannon, C. P., Sabatine, M. S. Identification of genetic variants associated with response to statin therapy Arteriosclerosis, thrombosis, and vascular biology. 2009;29(9):1310-5. Abstract

Murphy, S. A., Cannon, C. P., Wiviott, S. D., McCabe, C. H., Braunwald, E. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial Journal of the American College of Cardiology. 2009;54(25):2358-62. Abstract

Ray, K. K., Cannon, C. P., Cairns, R., Morrow, D. A., Ridker, P. M., Braunwald, E. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22 Arteriosclerosis, thrombosis, and vascular biology. 2009;29(3):424-30. Abstract

Tung, P., Wiviott, S. D., Cannon, C. P., Murphy, S. A., McCabe, C. H., Gibson, C. M. Seasonal variation in lipids in patients following acute coronary syndrome on fixed doses of Pravastatin (40 mg) or Atorvastatin (80 mg) (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 [PROVE IT-TIMI 22] Study) Am J Cardiol. 2009;103(8):1056-60.

Bangalore, S., Qin, J., Sloan, S., Murphy, S. A., Cannon, C. P. What is the optimal blood pressure in patients after acute coronary syndromes?: Relationship of blood pressure and cardiovascular events in the PRavastatin OR atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction (PROVE IT-TIMI) 22 trial Circulation. 2010;122(21):2142-51. Abstract

Califf, R. M., Lokhnygina, Y., Cannon, C. P., Stepanavage, M. E., McCabe, C. H., Musliner, T. A., Pasternak, R. C., Blazing, M. A., Giugliano, R. P., Harrington, R. A., Braunwald, E. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design Am Heart J. 2010;159(5):705-9.

Cannon, C. P., Shah, S., Dansky, H. M., Davidson, M., Brinton, E. A., Gotto, A. M., Stepanavage, M., Liu, S. X., Gibbons, P., Ashraf, T. B., Zafarino, J., Mitchel, Y., Barter, P. Safety of anacetrapib in patients with or at high risk for coronary heart disease N Engl J Med. 2010;363(25):2406-15. Abstract

Khera, A. V., Wolfe, M. L., Cannon, C. P., Qin, J., Rader, D. J. On-statin cholesteryl ester transfer protein mass and risk of recurrent coronary events (from the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 [PROVE IT-TIMI 22] study) Am J Cardiol. 2010;106(4):451-6. Abstract

Shiffman, D., Sabatine, M. S., Louie, J. Z., Kirchgessner, T. G., Iakoubova, O. A., Campos, H., Devlin, J. J., Sacks, F. M. Effect of pravastatin therapy on coronary events in carriers of the KIF6 719Arg allele from the cholesterol and recurrent events trial Am J Cardiol. 2010;105(9):1300-5. Abstract

Kohli, P., Cannon, C. P. Statins and safety: can we finally be reassured? Lancet. 2011;378(9808):1980-1.

Li, Y., Sabatine, M. S., Tong, C. H., Ford, I., Kirchgessner, T. G., Packard, C. J., Robertson, M., Rowland, C. M., Bare, L. A., Shepherd, J., Devlin, J. J., Iakoubova, O. A. Genetic variants in the KIF6 region and coronary event reduction from statin therapy Hum Genet. 2011;129(1):17-23. Abstract

Nazer, B., Ray, K. K., Sloan, S., Scirica, B., Morrow, D. A., Cannon, C. P., Braunwald, E. Prognostic utility of neopterin and risk of heart failure hospitalization after an acute coronary syndrome European heart journal. 2011;32(11):1390-7. Abstract

O'Donoghue ML, Braunwald E, White HD, Serruys P, Steg PG, Hochman J, Maggioni AP, Bode C, Weaver D, Johnson JL, Cicconetti G, Lukas MA, Tarka E, Cannon CP. Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome. Am Heart J. 2011;162:613-619. Abstract

Preiss, D., Seshasai, S. R., Welsh, P., Murphy, S. A., Ho, J. E., Waters, D. D., DeMicco, D. A., Barter, P., Cannon, C. P., Sabatine, M. S., Braunwald, E., Kastelein, J. J., de Lemos, J. A., Blazing, M. A., Pedersen, T. R., Tikkanen, M. J., Sattar, N., Ray, K. K. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis JAMA. 2011;305(24):2556-64. Abstract

Truong, Q. A., Murphy, S. A., McCabe, C. H., Armani, A., Cannon, C. P. Benefit of intensive statin therapy in women: results from PROVE IT-TIMI 22 Circ Cardiovasc Qual Outcomes. 2011;4(3):328-36. Abstract

Wilson, S. R., Sabatine, M. S., Wiviott, S. D., Ray, K. K., De Lemos, J. A., Zhou, S., Rifai, N., Cannon, C. P., Morrow, D. A., Timi Study Group Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Am Heart J. 2011;161(6):1147-55 e1. Abstract

Wiviott, S. D. ILLUMINATE sheds more light Circulation. 2011;124(5):536-7.

Bui, A. H., Bonaca, M. P., Sabatine, M. S., Ray, K. K., Rifai, N., Cannon, C. P., Morrow, D. A. Elevated concentration of placental growth factor (PlGF) and long term risk in patients with acute coronary syndrome in the PROVE IT-TIMI 22 trial J Thromb Thrombolysis. 2012;34(2):222-8. Abstract

Giugliano RP, Desai NR, Kohli P, Rogers WJ, Somaratne R, Huang F, Liu T, Mohanavelu S, Hoffman EB, McDonald ST, Abrahamsen TE, Wasserman SM, Scott R, Sabatine MS. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet. 2012;380:2007-2017. Abstract

Kohli, P., Cannon, C. P. Triglycerides: how much credit do they deserve? Med Clin North Am. 2012;96(1):39-55. Abstract

Kohli, P., Desai, N. R., Giugliano, R. P., Kim, J. B., Somaratne, R., Huang, F., Knusel, B., McDonald, S., Abrahamsen, T., Wasserman, S. M., Scott, R., Sabatine, M. S. Design and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy Clin Cardiol. 2012;35(7):385-91. Abstract

Kohli, Payal, Desai, Nihar R, Giugliano, Robert P, O'Donoghue, Michelle L, Somaratne, Ransi, Hoffman, Elaine B, Huang, Fannie, Wasserman, Scott M, Scott, Robert, Sabatine, Marc S Abstract 17630: Reduction in Lipoprotein (a) with the PCSK9 Inhibitor AMG145 in Hypercholesterolemic Patients on Background Statin: Results from the LAPLACE-TIMI 57 Trial Circulation. 2012;126(21 Supplement):A17630. Abstract

O'Malley, Ryan G, Morrow, David A, Bonaca, Marc P, Jarolim, Petr, Scirica, Benjamin M, Murphy, Sabina A, Conrad, Michael J, Cannon, Christopher P, Braunwald, Eugene, Sabatine, Marc S Abstract 11559: Determination of Cardiac Troponin with a Single-Molecule High-Sensitivity Assay and Outcomes in Patients with Stable Coronary Artery Disease: Analysis from PROVE IT-TIMI 22 Circulation. 2012;126(21 Supplement):A11559.

Udell, J. A., Scirica, B. M., Braunwald, E., Raz, I., Steg, P. G., Davidson, J., Hirshberg, B., Bhatt, D. L. Statin and aspirin therapy for the prevention of cardiovascular events in patients with type 2 diabetes mellitus Clin Cardiol. 2012;35(12):722-9. Abstract

Davidson, M., Liu, S. X., Barter, P., Brinton, E. A., Cannon, C. P., Gotto, A. M., Jr., Leary, E. T., Shah, S., Stepanavage, M., Mitchel, Y., Dansky, H. M. Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib J Lipid Res. 2013;54(2):467-72. Abstract

Desai, N. R., Kohli, P., Giugliano, R. P., O'Donoghue, M. L., Somaratne, R., Zhou, J., Hoffman, E. B., Huang, F., Rogers, W. J., Wasserman, S. M., Scott, R., Sabatine, M. S. AMG145, a Monoclonal Antibody Against Proprotein Convertase Subtilisin Kexin Type 9, Significantly Reduces Lipoprotein(a) in Hypercholesterolemic Patients Receiving Statin Therapy: An Analysis From the LDL-C Assessment With Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined With Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 Trial Circulation. 2013;128(9):962-9. Abstract

Gotto, A. M., Jr., Cannon, C. P., Li, X. S., Vaidya, S., Kher, U., Brinton, E. A., Davidson, M., Moon, J. E., Shah, S., Dansky, H. M., Mitchel, Y., Barter, P., Define Investigators Evaluation of Lipids, Drug Concentration, and Safety Parameters Following Cessation of Treatment With the Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Patients With or at High Risk for Coronary Heart Disease Am J Cardiol. 2013;NA(NA):NA. Abstract

Hochholzer, W., Giugliano, R. P. Does it make sense to combine statins with other lipid-altering agents following AIM-HIGH, SHARP and ACCORD? Curr Atheroscler Rep. 2013;15(1):290. Abstract

Kohli, Payal, Giugliano, Robert P. Low-Density Lipoprotein Lowering in 2013 by Nonstatin Agents: The Discovery and Development of Promising Novel Targeted Therapies Journal of Cardiovascular Pharmacology and Therapeutics. 2013;18(3):199-210.

Koren, M. J., Giugliano, R. P., Raal, F. J., Sullivan, D., Bolognese, M., Langslet, G., Civeira, F., Somaratne, R., Nelson, P., Liu, T., Scott, R., Wasserman, S. M., Sabatine, M. S., for the, Osler Investigators Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia: 52-Week Results From the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) Randomized Trial Circulation. 2013;NA(NA):NA. Abstract

Martinez, G., Rigotti, A., Acevedo, M., Navarrete, C., Rosales, J., Giugliano, R. P., Corbalan, R. Cholesterol Levels and the Association of Statins With In-Hospital Mortality of Myocardial Infarction Patients Insights From a Chilean Registry of Myocardial Infarction Clin Cardiol. 2013;NA(NA):NA. Abstract

Messe, S. R., Pervez, M. A., Smith, E. E., Siddique, K. A., Hellkamp, A. S., Saver, J. L., Bhatt, D. L., Fonarow, G. C., Peterson, E. D., Schwamm, L. H. Lipid Profile, Lipid-lowering Medications, and Intracerebral Hemorrhage After tPA in Get With The Guidelines-Stroke Stroke. 2013;44(5):1354-9. Abstract

Nazer, B., Ray, K. K., Murphy, S. A., Gibson, C. M., Cannon, C. P. Urinary albumin concentration and long-term cardiovascular risk in acute coronary syndrome patients: a PROVE IT-TIMI 22 substudy J Thromb Thrombolysis. 2013;36(3):233-9. Abstract

Nicholls, S. J., Kastelein, J. J., Schwartz, G. G., Bash, D., Rosenson, R. S., Cavender, M. A., Brennan, D. M., Koenig, W., Jukema, J. W., Nambi, V., Wright, R. S., Menon, V., Lincoff, A. M., Nissen, S. E., for the, Vista-Investigators Varespladib and Cardiovascular Events in Patients With an Acute Coronary Syndrome: The VISTA-16 Randomized Clinical Trial JAMA. 2013;NA(NA):NA. Abstract

O'Malley, R. G., Sabatine, M. S., Bonaca, M. P., Murphy, S., Jarolim, P., Conrad, M. J., Cannon, C. P., Braunwald, E. B., Morrow, D. A. Prognostic Performance of Srial High Sensitivity Cardiac Troponin Determination in Stable Ischemic Heart Disease: Analysis from PROVE IT-TIMI 22 Journal of the American College of Cardiology. 2013;61(10):A283.

Ojeifo, O., Wiviott, S. D., Antman, E. M., Murphy, S. A., Udell, J. A., Bates, E. R., Mega, J. L., Sabatine, M. S., O'Donoghue, M. L. Concomitant Administration of Clopidogrel With Statins or Calcium Channel Blockers: Insights From the TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38) Trial JACC Cardiovasc Interv. 2013;NA(NA):NA. Abstract

Udell, Jacob A, Bhatt, Deepak L, Hoffman, Elaine B, Cannon, Christopher P Abstract 10286: Benefit of High-Dose Atorvastatin in Patients With Acute Coronary Syndromes After Recent Influenza-like Illness: Results From the PROVE IT-TIMI 22 Trial Circulation. 2013;128(22 Supplement):A10286.

Gotto, A. M., Jr., Kher, U., Chatterjee, M. S., Liu, Y., Li, X. S., Vaidya, S., Cannon, C. P., Brinton, E. A., Moon, J. E., Shah, S., Dansky, H. M., Mitchel, Y., Barter, P. Lipids, Safety Parameters, and Drug Concentrations After an Additional 2 Years of Treatment With Anacetrapib in the DEFINE Study J Cardiovasc Pharmacol Ther. 2014;NA(NA):NA. Abstract

Kumbhani, D. J., Steg, P. G., Cannon, C. P., Eagle, K. A., Smith, S. C., Jr., Goto, S., Ohman, E. M., Elbez, Y., Sritara, P., Baumgartner, I., Banerjee, S., Creager, M. A., Bhatt, D. L., on Behalf of the, Reach Registry Investigators Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry Eur Heart J. 2014;NA(NA):NA. Abstract

Sarma, A., Cannon, C. P., de Lemos, J., Rouleau, J. L., Lewis, E. F., Guo, J., Mega, J. L., Sabatine, M. S., O'Donoghue, M. L. The Incidence of Kidney Injury for Patients Treated With a High-Potency Versus Moderate-Potency Statin Regimen After an Acute Coronary Syndrome J Am Heart Assoc. 2014;3(3):e000784. Abstract

Stein, E. A., Giugliano, R. P., Koren, M. J., Raal, F. J., Roth, E. M., Weiss, R., Sullivan, D., Wasserman, S. M., Somaratne, R., Kim, J. B., Yang, J., Liu, T., Albizem, M., Scott, R., Sabatine, M. S., for the, Proficio Investigators Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials Eur Heart J. 2014;NA(NA):NA. Abstract